Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Camizestrant · Etcamah, AZD-9833

Small molecule · Degrader of estrogen receptor alpha (ESR1) · developed by Astrazeneca

Approved FDA, Sep 2026

AZN Developer

2 Registered trials

What is Camizestrant?

Camizestrant is an oral estrogen receptor antagonist and selective estrogen receptor degrader (SERD) that binds the ligand binding domain of ERα and induces its proteasome-dependent degradation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Etcamah, AZD-9833
Drug type: Small molecule
Targets: estrogen receptor alpha (ESR1)
Mechanism: Degrader of estrogen receptor alpha (ESR1)
Pathways: ER-mediated signaling
Therapy area: Oncology
Developer: Astrazeneca (AZN)
FDA status: Approved as Etcamah (September 4, 2026), NDA220359 · FDA label
UNII: JUP57A8EPZ

✅ FDA-approved uses

HR-positive, HER2-negative, locally advanced or metastatic breast cancer with ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy

From the indications section of the FDA label (version of Sep 4, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04711252	Phase 3	ER-Positive HER2-Negative Breast Cancer	Active not recruiting	AZN
NCT07427394	Phase 2	Advanced Breast Cancer	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Breast CancerER-Positive HER2-Negative Breast Cancer

Other drugs acting on ESR1

Ethinyl Estradiol/Levonorgestrel FDA approved Imlunestrant FDA approved Segesterone Acetate and Ethinyl Estradiol FDA approved Tamoxifen FDA approved Vepdegestrant FDA approved Giredestrant Phase 1/2 Zuclomiphene Phase 2

More from Astrazeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1 AZD5492 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Camizestrant

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z